-
Domestic CAR-T therapy listed the second! After raising $100 million in the round of the drug- and financial giant noir B-round, or list hong Kong stocks. The doctor was bombarded with explosives.
Time of Update: 2020-07-18
Focusing on four popular biomedical fields, including tumor immunity, new antibodies, stem cell regenerative medicine and gene therapy, the 2020 bpit biopharmaceutical innovation technology conference will be held in Nanjing International Youth Culture Center, China, on July 19-21, 2020!
-
Nat Comm . . . Chen's team reveals the mechanism by which human intestinal microbiome disorders contribute to the onset of intracranial aneurysms and provides new intervention strategies.
Time of Update: 2020-07-18
the results showed that exogenous taurine supplementation after transplantation significantly reduced the overall incidence of intracranial aneurysms compared with mice transplanted with faeces from patients with aneurysms.
-
Nat Genetics . . . Zhang's/Liu Yu team worked to develop a non-coding mutation analysis method for individualized tumors for individual cases.
Time of Update: 2020-07-18
98% of the human genome is noncoding, and more than 80% of the noncoding genome contains DNA functional elements (such as promoters, enhancers, etc.), which have the function of gene transcription reg
-
Best CP! There is a new breakthrough in the treatment of advanced gastric cancer in the combination of "k drug and lunvalitini".
Time of Update: 2020-07-18
recently, the Lancet Oncology published a phase II clinical study on the efficacy and safety of the combination in patients with advanced gastric cancer and esophageal gastric junction adenocarcinoma (epoc1706).
-
U.S. scientists have discovered a specific site of dna methylation imbalance that is the key to cancer.
Time of Update: 2020-07-18
the title is "allele specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease associated regulation By sequencing and analyzing the entire genome of cancer and healthy tissues, researchers have discovered the key to cancer and other disease risks: specific sites in DNA with imbalanced methylation.
-
TIGIT Target - Development.
Time of Update: 2020-07-18
and a phase III clinical trial of tiragolumab, skyscraper-02 (nct04256421), aims to detect whether the increase of tiragolumab has an effect on the treatment of extensive stage small cell lung cancer (first-line) on the basis of atezolizumab combined with chemotherapy.
-
Lung scale cancer heart encapsulation fluid, where to go from? Look at immunotherapy and fight and go.
Time of Update: 2020-07-18
Evaluation of curative effect: chest CT examination on June 25, 2019: after left lung cancer surgery, compared with 2019-5-0-30, some nodules in right lower lobe of lung slightly reduced, pericardial effusion.
-
The preferred strategy of new auxiliary treatment of breast cancer is discussed and the preferred strategy is discussed.
Time of Update: 2020-07-18
The study of train-2 showed that in the neoadjuvant treatment of HER2 positive breast cancer, there was no difference in the PCR rate between double target combination of anthracyclines and non anthracyclines (67% vs 68%, P = 0.95), and 3-year event free survival (EFS) was observed There was no significant difference in the overall survival (OS) rate and 3-year survival rate, but anthracycline was more toxic.
-
HCC risk prediction model for patients with chronic hepatitis B - The Hope of Precision Medicine- A review of high scores.
Time of Update: 2020-07-18
In the past 10 years, more than 12 risk scoring models have been developed to predict the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). these scoring models divide
-
The study of pancreatic cancer, which is slow to progress, has seen a major update in the guidelines. CSCO guide!
Time of Update: 2020-07-18
Table 3 treatment principles of metastatic pancreatic cancer, chemotherapy combined with electric field therapy was added in the recommendation of grade III experts, and the update was based on the phase II PANOVA study.
-
Physician's Journal Morning Post: IS PSA typical of overdiagnosis and overtreatment?
Time of Update: 2020-07-18
for example, in ERSPC, the cumulative incidence rate of prostate cancer in the screening group was 13.3% in the 16 years, and 10.3% in the control group, and the relative risk of prostate cancer diagnosed in the screening group decreased compared with the control group with the longer follow-up time.
-
Comprehensive analysis of molecular and clinical characteristics of 1000 children with low-grade glioma.
Time of Update: 2020-07-18
Children with low-grade gliomas (pLGG) are children with a common brain tumor, accounting for about 30% Unlike adult symitomas, which occur primarily in the hemisphere of the brain and inevitably turn
-
Local advanced esophageal cancer: comparison between proton beam therapy and in vitro radiation therapy.
Time of Update: 2020-07-18
to determine whether the use of proton beam radiation therapy instead of conventional external radiotherapy can reduce the toxicity of radiotherapy and chemotherapy without affecting the efficacy, a multicenter, randomized, phase 2 trial involving 107 patients with locally advanced esophageal cancer (median age, 67 years) was conducted.
-
New Findings: Retrospective Cohort Study: Common hypertension drugs may reduce the risk of colorectal cancer.
Time of Update: 2020-07-18
propensity score regression adjustment was performed on 23 covariates (including patient factors, concurrent medication and endoscopic center performance) with angiotensin converting enzyme inhibitor / angiotensin receptor blocker (used within 5 years before colonoscopy ≥ 180 days), and the adjusted risk ratio of colorectal cancer was obtained.
-
Based on immunology analysis of tumor distype, this idea is worth learning from!
Time of Update: 2020-07-18
The results showed that: (1) identification and validation of immune subtypes of diffuse low-grade gliomas, based on 782 previously reported immune related genes, the authors used consensus clustering method to identify the immune subtypes of diffuse low-grade gliomas The data sets of 402 diffuse LGG samples were clustered (50 iterations, 80% resampling rate).
-
The fourth generation of ALK inhibitor TPX-0131 made a stunning debut.
Time of Update: 2020-07-18
Tpx-0131 is the most effective inhibitor for a series of EML4-ALK compound mutations, while the 1st, 2nd and 3rd generation ALK drugs show lower activity and sensitivity (Table 3).
-
Bladder cancer hit! Merck/Pfizer Bavencio's first-line maintenance therapy is approved by the U.S. FDA, significantly extending survival!
Time of Update: 2020-07-18
, July 01, 2020 / PRNewswire/ -- Merck KGaA and partner Pfizer have jointly announced that the U.S Food and Drug Administration ( FDA ) has approved anti-PD-L1 therapy Baven (avelumab) for the m
-
New Discovery: Obesity is a delay again! Large retrospective analysis showed that chemotherapy was poor in obese breast cancer patients.
Time of Update: 2020-07-18
based on a retrospective analysis of data from large clinical trials, an international team of researchers concluded that overweight or obese breast cancer patients are much less effective than ordinary patients receiving docetaxel, one of the most widely used chemotherapy drugs in the world.
-
2020 version of the CSCO gastric cancer guide three important update points, a clear article!
Time of Update: 2020-07-18
Molecular diagnosis, the treatment of resectable gastric cancer and the drug treatment of advanced metastatic gastric cancer have these updates! At this boa / BOC online conference, Professor Wang Fen
-
"2020 POST ASCO" Seminar on the Latest Progress in Lymphoma successfully concluded!
Time of Update: 2020-07-18
topic 6: progress in the treatment of mantle cell lymphoma Professor Zhang Qingyuan, Affiliated Tumor Hospital of Harbin Medical University, presented a wonderful keynote speech on "progress in the treatment of mantle cell lymphoma (MCL)".
